natgillin/translations-raw huggingface dataset:
In the study of rheumatoid arthritis patients with an inadequate response to TNF blockers in the past, adding Orencia to existing treatment led to 50% of the patients having a reduction in symptoms (129 out of 256) after 6 months, compared with 20% of the patients adding placebo (26 out of 133).
U ispitivanju na bolesnicima s reumatoidnim artritisom koji u prošlosti nisu na odgovarajući način reagirali na TNF blokatore, dodavanjem lijeka Orencia postojećoj terapiji došlo je do ublažavanja simptoma kod 50 % bolesnika (129 od 256) nakon šest mjeseci, u usporedbi s 20 % kod bolesnika kojima je dodan placebo (26 od 133).
In the study of smoke inhalation, the response to Cyanokit was assessed as ‘positive’ in 31 patients (45%), ‘partial’ in 15 (22%) and ‘absent’ in 10 (15%).
U ispitivanju udisanja dima, odgovor na Cyanokit ocijenjen je kao "pozitivan" u 31 bolesnika (45%), "djelomičan" u 15 (22%) i "odsutan" u 10 (15%).
In the study of Tarceva used in combination with gemcitabine for pancreatic cancer, the most common side effects were tiredness (seen in 73% of patients), rash (seen in 69% of patients) and diarrhoea (seen in 48% of patients).
U ispitivanju primjene lijeka Tarceva u kombinaciji s gemcitabinom u bolesnika s rakom gušterače najčešće nuspojave bile su umor (zabilježen u 73 % bolesnika), osip (zabilježen u 69 % bolesnika) i proljev (zabilježen u 48 % bolesnika).
In the study on newly diagnosed Ph+ patients with chronic phase CML, Sprycel was more effective than imatinib: within one year, 77% of patients receiving Sprycel no longer had the Philadelphia chromosome in their blood cells, compared with 66% of patients receiving imatinib.
U ispitivanju provedenom na novodijagnosticiranim Ph+ bolesnicima sa KML-om u kroničnoj fazi, Sprycel je bio djelotvorniji od imatiniba: unutar godine dana 77% bolesnika koji su primali Sprycel u svojoj krvi više nije imalo Philadelphia kromosom u usporedbi sa 66% bolesnika koji su primali imatinib.
In the study PIX 301, decreased ejection fraction occurred in 13 patients (19.1%) in the Pixuvri group.
U ispitivanju PIX 301, u skupini koja je primala Pixuvri, smanjena ejekcijska frakcija pojavila se u 13 bolesnika (19,1%).
In the study using a fixed dose of Kineret, 38% of the patients adding Kineret had at least a 20% reduction in symptoms after six months, compared with 22% of those adding placebo.
U ispitivanju je korištena nepromijenjena doza lijeka Kineret, te je 38 % bolesnika s dodanim lijekom Kineret imalo najmanje 20 %-tno smanjenje simptoma nakon šest mjeseci, u usporedbi s 22 % bolesnika kojima je dodan placebo.
In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 4) compared with warfarin.
U ispitivanju je apiksaban bio statistički značajno uspješniji od varfarina u primarnoj mjeri ishoda - sprječavanju moždanog udara (hemoragijskog ili ishemijskog) i sistemske embolije (vidjeti Tablicu 4).
In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic or ischaemic) and systemic embolism (see Table 6) compared with warfarin.
U ispitivanju je apiksaban bio statistički značajno uspješniji od varfarina u primarnoj mjeri ishoda - sprječavanju moždanog udara (hemoragijskog ili ishemijskog) i sistemske embolije (vidjeti Tablicu 6).
In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 6) compared to ASA.
U ispitivanju je apiksaban bio statistički značajno uspješniji u primarnom ishodu - sprječavanju moždanog udara (hemoragijskog ili ishemijskog) i sistemske embolije (vidjeti Tablicu 6) u usporedbi s ASK-om.
In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 8) compared to ASA.
U ispitivanju je apiksaban bio statistički značajno uspješniji u primarnom ishodu - sprječavanju moždanog udara (hemoragijskog ili ishemijskog) i sistemske embolije (vidjeti Tablicu 8) u usporedbi s ASK-om.
In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 8).
U ispitivanju, apiksaban nije bio inferioran enoksaparinu/varfarinu u kombiniranom primarnom ishodu utvrđenog ponavljajućeg simptomatskog venskog tromboembolijskog događaja (nefatalna DVT ili nefatalna PE) ili smrtnom ishodu povezanom s VTE (vidjeti Tablicu 10).
In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value < 0.0001] (see Table 9).
U ispitivanju je apiksaban bio statistički uspješniji od enoksaparina/varfarina u primarnom sigurnosnom ishodu [Relativni rizik 0,31, 95%-tni interval pouzdanosti (0,17, 0,55), P-vrijednost < 0,0001] (vidjeti Tablicu 11).
In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value <0.0001] (see Table 11).
U ispitivanju je apiksaban bio statistički uspješniji od enoksaparina/varfarina u primarnom sigurnosnom ishodu [Relativni rizik 0,31, 95%-tni interval pouzdanosti (0,17, 0,55), P-vrijednost <0,0001] (vidjeti Tablicu 11).
In the study, Cabometyx was compared with the cancer medicine everolimus.
Cabometyx je u ispitivanju uspoređen s everolimusom, drugim lijekom za liječenje raka.
In the study, Jinarc was compared with placebo (a dummy treatment) and the main measure of effectiveness was the change in kidney size after 3 years of treatment (a way of measuring the swelling caused by cyst formation).
U ispitivanju je Jinarc uspoređen s placebom (prividnim liječenjem), a glavna mjera djelotvornosti bila je promjena u veličini bubrega nakon 3 godine terapije (tako što je izmjeren oteklina koju je uzrokovalo formiranje ciste).
In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo.
U ispitivanju, incidencija u značajnom krvarenju obje doze apiksabana nije se statistički razlikovala od placeba.
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
U ispitivanju rizik olanzapina bio je usporediv s rizikom za atipične antipsihotike uključene u skupnu analizu.
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
U ispitivanju, rizik olanzapina bio je usporediv s rizikom za atipične antipsihotike uključene u objedinjenu analizu.
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
U ispitivanju, rizik olanzapina bio je usporediv s rizikom za atipične antipsihotike uključene u skupnu analizu.
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL (no observed adverse effect level) of 5 mg/kg was identified.
U ispitivanju supkutane primjene i plodnosti kod štakora, nisu primijećeni poremećaji kod mužjaka, no kod ženki je poremećena plodnost, a NOAEL (no observed adverse effect level, neprimijećena razina nuspojava) je identificiran pri 5 mg/kg.
In the subgroup aged > 65 years the percentage of vaccinees with rSBA titres ≥ 128 at one month post- vaccination ranged from 90% (group A) to 97% (group Y).
U podskupini ispitanika starijih od 65 godina, postotak cijepljenika koji su mjesec dana nakon cijepljenja imali rSBA titre ≥ 128 kretao se u rasponu od 90% (grupa A) do 97% (grupa Y).
In the subgroup aged > 65 years the percentage of vaccinees with rSBA titres ≥ 128 at one month post-vaccination ranged from 90% (group A) to 97% (group Y).
U podskupini ispitanika starijih od 65 godina, postotak cijepljenika koji su mjesec dana nakon cijepljenja imali rSBA titre ≥ 128 kretao se u rasponu od 90% (grupa A) do 97% (grupa Y).
In the subgroup analyses of prior cisplatin use versus BSC for progression free survival (PFS), the results were: HR (95% CI) = [0.55 (0.34 – 0.89); p=0.0129] in the absence of prior cisplatin, and a HR (95% CI) = [0.64 (0.48 – 0.85); p=0.0040] in the presence of prior cisplatin.
U analizama preživljenja bez progresije bolesti (PFS) u podskupina bolesnika s prethodnom primjenom cisplatina i onih koje su primali BSC, dobiveni su sljedeći rezultati: omjer hazarda (HR) (95%-tni CI) = [0,55 (0,34 – 0,89); p=0,0129] bez prethodne primjene cisplatina i omjer hazarda (HR) (95%-tni CI) = [0,64 (0,48 – 0,85); p=0,0040] uz prethodnu primjenu cisplatina.
In the subgroup of patients with HR ≥ 75 bpm (n=4150), a greater reduction was observed in the primary composite endpoint of 24 % (hazard ratio: 0.76, 95%CI [0.68;0.85] – p<0.0001) and for other secondary endpoints, including all cause death (hazard ratio: 0.83, 95%CI [0.72;0.96] – p=0.0109) and CV death (hazard ratio: 0.83, 95%CI [0.71;0.97] – p=0.0166).
U podskupini bolesnika sa srčanom frekvencijom ≥ 75/min (n=4 150), zabilježeno je izraženije smanjenje primarnog kompozitnog ishoda od 24% (omjer hazarda (HR): 0,76, 95%CI [0,68;0,85] – p<0,0001) kao i za ostale sekundarne ishode, uključujući smrt zbog svih uzroka (omjer hazarda (HR): 0,83, 95%CI [0.72;0.96] – p=0,0109) i smrt zbog kardiovaskularnih uzroka (omjer hazarda (HR): 0,83, 95%CI [0.71;0.97] – p=0,0166).
In the subgroup of patients with recent symptom onset (< 3 years) the clinical benefit of ChondroCelect over microfracture was significantly larger, confirming the results at 36 months after treatment.
U podskupini bolesnika s nedavnom pojavom simptoma (<3 godine) klinička korist liječenjem lijekom ChondroCelect naspram liječenja mikrofrakturom bila je značajno veća, što potvrđuje rezultate opažene 36 mjeseci nakon liječenja.
In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and
U podskupinama liječenim inzulinom sa ili bez istodobne primjene metformina prosječno sniženje HbA1c, prilagođeno s obzirom na placebo, bilo je
In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and
U podskupinama liječenim inzulinom sa ili bez istodobne primjene metformina srednje sniženje HbA1c, prilagođeno s obzirom na placebo, bilo je
In the subjects aged 3 to 5 and 6 to 9 years old who received two doses of either a full or a half dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1), the anti-HA antibody responses against A/Indonesia/5/2005 at day 42 were as follows:
U ispitanika u dobi od 3 do 5 i 6 do 9 godina koji su primili dvije doze i to ili dvije cijele doze ili dvije polovine doze AS03-adjuvantiranog cjepiva koje sadrži 3,75 µg hemaglutinina dobivenog iz soja A/Vietnam/1194/2004 (H5N1), odgovori anti-HA protutijela na soj A/Indonesia/5/2005, na 42. dan, bili su sljedeći:
In the subjects aged 3 to 5 and 6 to 9 years old who received two doses of either a full or a half dose of AS03-adjuvanted vaccine containing 3.75 µg HA derived from A/Vietnam/1194/2004 (H5N1), the anti-HA antibody responses at day 42 were as follows:
U ispitanika u dobi od 3 do 5 i od 6 do 9 godina koji su primili ili dvije pune doze ili dvije polovine doze AS03-adjuvantiranog cjepiva koje sadrži 3,75 µg hemaglutinina dobivenog iz soja A/Vietnam/1194/2004 (H5N1), odgovori anti-HA protutijela na 42. dan bili su sljedeći:
In the subjects over 65 years, the mean decreases at the various time points were between 5 and 15 mmHg (systolic) and 0 and 10 mmHg (diastolic).
U ispitanika starijih od 65 godina, srednje rvijednosti smanjenja u različitim vremenskim točkama bile su između 5 i 15 mmHg (sistolički) i 0 i 10 mmHg (dijastolički).
In the subjects over 65 years, the mean decreases at the various time points were between 5 and 15 mmHg (systolic) and 0 and 10 mmHg (diastolic).
U ispitanika starijih od 65 godina, srednje vrijednosti smanjenja u različitim vremenskim točkama bile su između 5 i 15 mmHg (sistolički) i 0 i 10 mmHg (dijastolički).
In the subpopulation of patients receiving glucocorticoids for more than 3 months prior to randomisation, zoledronic acid increased lumbar spine BMD by 4.06% versus 2.71% for risedronate (mean difference: 1.36% ; p<0.001).
U subpopulaciji bolesnika koji su primali glukokortikoide dulje od 3 mjeseca prije randomizacije zoledronatna kiselina povisila je BMD lumbalne kralježnice za 4,06% u usporedbi sa 2,71% pri primjeni risedronata (srednja vrijednost razlike: 1,36%; p<0,001).
In the subpopulation of patients that had received glucocorticoids for 3 months or less prior to randomisation, zoledronic acid increased lumbar spine BMD by 2.60% versus 0.64% for risedronate (mean difference: 1.96%; p<0.001).
U subpopulaciji bolesnika koji su primali glukokortikoide 3 mjeseca ili kraće prije randomizacije zoledronatna kiselina povećala je BMD lumbalne kralježnice za 2,60% u odnosu na 0,64% pri primjeni risedronata (srednja razlika: 1,96%; p<0,001).
In the subset of 6 children aged 3 – 5 who were compliant with their drug regimen, the mean AUC was 147 M·h, which was 23 % lower than expected.
In podskupini sa 6 djece u dobi od 3-5 godina koja su se pridržavala režima uzimanja lijeka, prosječan AUC iznosio je 147 M·h, što je 23% manje od očekivanog.
In the subset of patients requiring courses of OCS treatment for management of their asthma exacerbation, reslizumab was shown to reduce the frequency of asthma exacerbations by 56% (p<0.0001) and 60% (p<0.0001) in Study I and Study II, respectively.
U podskupini bolesnika kojima su bile potrebne terapijske kure peroralnim kortikosteroidima zbog liječenja egzacerbacije astme pokazalo se da je reslizumab smanjio učestalost egzacerbacija astme za 56 % (p<0,0001) u Ispitivanju I i 60 % (p<0,0001) u Ispitivanju II.
In the subset of patients with a medical history of elevated transaminases, increased ALT or AST have been reported more frequently in patients receiving ivacaftor compared to placebo.
U podskupini bolesnika s povišenim transaminazama u povijesti bolesti, povišene vrijednosti ALT ili AST bile su zabilježene češće u onih koji su primali ivakaftor nego u onih koji su primali placebo.
In the subset of patients with genotype 1 infection and low viral load (< 600,000 IU/ml) who become HCV-RNA negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i.e. overall 48 weeks treatment duration).
U podskupini bolesnika s infekcijom genotipa 1 i malim virusnim opterećenjem (< 600 000 IU/ml) koji postanu HCV-RNK negativni u 4. tjednu liječenja i ostanu HCV-RNK negativni u 24. tjednu, liječenje se može ili prekinuti nakon ta 24 tjedna liječenja ili nastaviti tijekom dodatna 24 tjedna (tj. ukupno trajanje liječenja od 48 tjedana).
In the subset of steroid naive asthmatics the time to an individual well controlled week was 16 days in the salmeterol/fluticasone propionate treatment compared with 23 days following treatment with ICS.
prije nisu bili liječeni inhalacijskim kortikosteroidom, vrijeme do individualnog dobro kontroliranog tjedna iznosilo je 16 dana u skupini koja je primala liječenje salmeterolom/flutikazonpropionatom u usporedbi s 23 dana kod liječenja inhalacijskim kortikosteroidom.
In the subset of subjects aged 19-55 years who were seronegative at baseline, the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 67% (582/875); serogroup C 71% (401/563); serogroup W135 82% (131/160); serogroup Y 66% (173/263).
U podskupini ispitanika u dobi između 19 i 55 godina koji su bili seronegativni na početku, udio ispitanika koji su postigli hSBA ≥ 1:8 nakon primanja doze cjepiva Menveo navedeni su u nastavku: serogrupa A 67% (582/875); serogrupa C 71% (401/563); serogrupa W135 82% (131/160); serogrupa Y 66% (173/263).
In the substudy 108 subjects were randomized 1:1 in double blinded fashion to receive abatacept at doses approximating 10 mg/kg (ABA 10) or 5 mg/kg (ABA 5).
U tom je podispitivanju 108 ispitanika randomizirano na dvostruko slijepi način u omjeru 1:1 da primaju abatacept u dozama od približno 10 mg/kg (ABA 10) ili 5 mg/kg (ABA 5).
In the substudy of study VI, patients who had achieved remission at 2 years (DAS 28 ESR < 2.6) and after at least 1 year of treatment with abatacept in Study VI were eligible to enter a substudy.
Bolesnici koji su nakon 2 godine postigli remisiju (DAS28 ESR [sedimentacija eritrocita] < 2,6) i najmanje godinu dana su bili liječeni abataceptom u Ispitivanju VI, mogli su se uključiti u podispitivanje u sklopu Ispitivanja VI.
In the supportive study MCL-001, approximately 10% of subjects experienced TFR; all report were Grade 1 or 2 in severity and all were assessed as treatment-related.
U dodatnom ispitivanju MCL-001, reakciju razbuktavanja tumora imalo je približno 10% ispitanika; svi zabilježeni slučajevi bili su 1. ili 2. stupnja težine i za sve je procijenjeno da su povezani s liječenjem.
in the syringe, hold the syringe with the needle pointing upwards and gently flick the syringe until all the air collects at the top.
zraka u štrcaljki, držite štrcaljku s iglom uperenom prema gore i lagano je kucnite sve dok se zrak ne skupi na vrhu.
In the table below all adverse reactions are listed by system organ class and by frequency.
U niže navedenoj tabeli navedene su sve nuspojave prema klasifikaciji organskih sustava i prema učestalosti.
In the table below all adverse reactions, which were identified based on the review of the full Eslicarbazepine acetate safety database are presented by System Organ Class and frequency.
U tablici u nastavku sve nuspojave, koje su identificirane na temelju pregleda cijele baze podataka o sigurnosti primjene eslikarbazepinacetata navedene su prema klasifikaciji sustava organa i učestalosti.
In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000)..
U donjoj tablici navedene su sve medicinski značajne nuspojave koje su se javile u kliničkim ispitivanjima s incidencijom većom nego kod placeba razvrstane prema organskim sustavima i učestalosti (vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1000)).
In the table below the specific pharmacokinetic enhancer is specified when recommendeations differ.
U tablici ispod, određeni farmakokinetički pojačivač naveden je posebno, ako se preporuke razlikuju.
In the table below, adverse reactions reported in all clinical studies and in the worldwide post-marketing experience for which a reasonable causal relationship exists are listed by MedDRA system organ class and frequency: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from available data).
U sljedećoj su tablici nuspojave zabilježene u svim kliničkim ispitivanjima nakon stavljanja lijeka u promet u svijetu za koje postoji razuman uzročno-posljedični odnos navedene prema MedDRA klasifikaciji organskih sustava i učestalosti: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000); vrlo rijetko (<1/10 000), nepoznato (se ne može procijeniti iz dostupnih podataka).
In the table below, adverse reactions reported in the double-blind period of the Phase 3 study are listed by MedDRA system organ class and frequency: very common (≥ 1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
U donjoj su tablici navedene nuspojave, prijavljene u dvostruko slijepom razdoblju ispitivanja faze III, u skladu s MedDRA klasifikacijom organskih sustava i učestalosti: vrlo često (≥ 1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10.000 do <1/1000); vrlo rijetko (<1/10.000).
In the table below, adverse reactions, which were identified based on review of the full brivaracetam clinical studies safety database, are listed by System Organ Class and frequency.
Nuspojave identificirane na temelju pregleda cjelovite baze podataka o sigurnosti iz kliničkih ispitivanja brivaracetama navedene su u tablici u nastavku prema organskom sustavu i učestalosti.
In the Tarceva plus gemcitabine arm, Grade 3/4 rash and diarrhoea were each reported in 5% of patients.
U skupini koja je primala lijek Tarceva i gemcitabin osip i proljev stupnja intenziteta 3/4 prijavljeni su u 5% bolesnika.
In the tenofovir disoproxil fumarate treatment arm, 7% of patients discontinued treatment due to an adverse event; 9% of patients experienced a confirmed increase in serum creatinine of ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl through week 48; there were no statistically significant differences between the combined tenofovir-containing arms and the entecavir arm.
U skupini koja je primala tenofovirdizoproksilfumarat, 7% pacijenata prekinulo je liječenje zbog jedne od nuspojava, 9% pacijenata imalo je dokazano povećanje serumskog kreatinina od > 0,5 mg/dl ili dokazano povećanje serumskih fosfata od < 2 mg/dl kroz 48 tjedana; nije bilo statistički značajnih razlika između skupina koje su primale kombinirano liječenje tenofovirdizoproksilom i skupine na entekaviru.
In the tenofovir disoproxil fumarate treatment arm, 7% of patients discontinued treatment due to an adverse event; 9% of patients experienced a confirmed increase in serum creatinine of ≥ 0.5 mg/dl or confirmed serum phosphate of < 2 mg/dl through week 48; there were no statistically significant differences between the combined tenofovir-containing arms and the entecavir arm.
U skupini koja je primala tenofovirdizoproksilfumarat, 7% pacijenata prekinulo je liječenje zbog jedne od nuspojava, 9% pacijenata imalo je dokazano povećanje serumskog kreatinina od > 0,5 mg/dl ili dokazano povećanje serumskih fosfata od <2 mg/dl kroz 48 tjedana; nije bilo statistički značajnih razlika između skupina koje su primale kombinirano liječenje tenofovirdizoproksilom i skupine na entekaviru.
In the third study dyspnoea was reported more frequently following Rapiscan (18% for patients with COPD; 11% for patients with asthma) than placebo, but at a lower rate than reported during clinical development (see Section 4.8).
U trećem ispitivanju dispneja je prijavljena češće nakon primjene Rapiscana (18% bolesnika s KOBP; 11% bolesnika s astmom) nego placeba, ali s manjom stopom prijava nego tijekom kliničkog razvoja lijeka (vidjeti dio 4.8).
In the third study in 1009 patients with mild or moderate asthma (n=537) and moderate or severe COPD (n=472) the incidence of FEV1 reduction >15% from baseline was 1.1% and 2.9% in patients with asthma (p=0.15) and 4.2% and 5.4% in patients with COPD (p=0.58) following Rapiscan and placebo dosing, respectively.
U trećem ispitivanju na 1009 bolesnika s blagom do umjerenom astmom (n=537) i umjerenom do teškom KOBP (n=472) incidencija smanjenja FEV1 >15% od polaznih vrijednosti bila je 1,1% odnosno 2,9% u bolesnika s astmom (p=0,15) i 4,2% odnosno 5,4% u bolesnika s KOBP (p=0,58) nakon primjene doze Rapiscana odnosno placeba.
In the third study in adults with hepatitis B and decompensated liver disease, 70% of patients taking Viread or entecavir had a viral level below 400 copies/ml.
U trećem ispitivanju u odraslih osoba s hepatitisom B i dekompenziranom bolešću jetre, 70% bolesnika koji su uzimali lijekove Viread ili entecavir imalo je razinu virusa manju od 400 kopija/ml.
In the third study in women weighing 50 kg or more, 24 and 27% of women treated with Elonva and follitropin beta respectively became pregnant.
U trećem ispitivanju u žena s 50 kg ili više, zatrudnjelo je 24 i 27% žena liječenih Elonvom, odnosno folitropinom beta.